Pegvisomant in acromegaly: Why, when, how

Journal of Endocrinological Investigation

Volumn 30, Issue 8, 2007, Pages 693-699

  Colao, A ^a   Arnaldi, G ^b   Beck Peccoz, P ^c   Cannavo S ^d   Cozzi, R ^e   degli Uberti, E ^f   De Marinis, L ^g   De Menis, E ^h   Ferone, D ⁱ   Gasco, V ^j   Giustina, A ^k   Grottoli, S ^j   Lombardi, G ^a   Maffei, P ^l   Martino, E ^m   Minuto, F ⁱ   Pivonello, R ^a   Ghigo, Ezio ^j  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

^e OSPEDALE NIGUARDA CA GRANDA   (Italy)

^f UNIVERSITY OF FERRARA   (Italy)

^g CATHOLIC UNIVERSITY   (Italy)

^h Tevizo Hospital   (Italy)

ⁱ UNIVERSITY OF GENOA   (Italy)

^j UNIVERSITY OF TURIN   (Italy)

^k UNIVERSITY OF BRESCIA   (Italy)

^l UNIVERSITY OF PADOVA   (Italy)

^m UNIVERSITY OF PISA   (Italy)

more..

Author keywords

Acromegaly; Medical Therapy; Pegvisomant

Indexed keywords

AMYLASE; ANGIOPEPTIN; ANTIDIABETIC AGENT; HORMONE RECEPTOR BLOCKING AGENT; OCTREOTIDE; PEGVISOMANT; PLACEBO; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOSTATIN DERIVATIVE; TRIACYLGLYCEROL LIPASE; DRUG DERIVATIVE; HUMAN GROWTH HORMONE;

ACROMEGALY; ACUTE PANCREATITIS; AMYLASE BLOOD LEVEL; ARTICLE; BONE DENSITY; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; GALLSTONE; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; HORMONE RELEASE; HUMAN; HYPERTENSION; HYPOPHYSIS TUMOR; INJECTION SITE REACTION; INSULIN SENSITIVITY; LIPOHYPERTROPHY; LIVER FUNCTION TEST; LIVER TOXICITY; LOADING DRUG DOSE; MONOTHERAPY; OPTIMAL DRUG DOSE; OSTEOPOROSIS; SIDE EFFECT; SWELLING; TREATMENT FAILURE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR VOLUME; HYPOPHYSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ACROMEGALY; HUMAN GROWTH HORMONE; HUMANS; PITUITARY GLAND;

EID: 35448948375     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03347452     Document Type: Article

References (33)

1. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004, 25: 102-52.
2. Melmed S. Medical progress: Acromegaly. N Engl J Med 2006, 355: 2558-73.
3. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005, 90: 4465-73.
4. Melmed S, Sternberg R, Cook D, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005, 90: 4405-10.
5. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 2002, 23: 623-46.
6. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000, 342: 1171-7.
7. van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001, 358: 1754-9.
8. Colao A, Pivonello R, Auriemma RS, et al. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 2006, 154: 467-77.
9. Schreiber I, Buchfelder M, Droste M, et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 2007, 156: 75-82.
10. Jehle S, Reyes CM, Sundeen RE, Freda PU. Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly. J Clin Endocrinol Metab 2005, 90: 1588-93.
11. Ronchi CL, Varca V, Beck-Peccoz P, et al. Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab 2006, 91: 121-8.
12. Lindberg-Larsen R, Møller N, Schmitz O, et al. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. J Clin Endocrinol Metab 2007, 92: 1724-8.
13. Drake WM, Rowles SV, Roberts ME, et al. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur J Endocrinol 2003, 149: 521-7.
14. Sesmilo G, Fairfield WP, Katznelson L, et al. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab 2002, 87: 1692-9.
15. Pivonello R, Galderisi M, Auriemma RS, et al. Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. J Clin Endocrinol Metab 2007, 92: 476-82.
16. Bonadonna S, Mazziotti G, Nuzzo M, et al. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res 2005, 20: 1837-44.
17. Fairfield WP, Sesmilo G, Katznelson L, et al. Effects of a growth hormone receptor antagonist on bone markers in acromegaly. Clin Endocrinol (Oxf) 2002, 57: 385-90.
18. Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A, Trainer PJ. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab 2003, 88: 5650-5.
19. Biering H, Saller B, Bauditz J, et al. German pegvisomant investigators. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. Eur J Endocrinol 2006, 154: 213-20.
20. Besser GM, Burman P, Daly AF. Predictors and rates of treatment -resistant tumor growth in acromegaly. Eur J Endocrinol 2005, 153:187-93.
21. Maffei P, Martini C, Pagano C, Sicolo N, Corbetti F. Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist pegvisomant. Ann Intern Med 2006, 145: 310-2.
22. Brian SR, Bidlingmaier M, Wajnrajch MP, Weinzimer SA, Inzucchi SE. Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects. J Clin Endocrinol Metab 2007, 92: 3374-7.
23. Bevan JS. Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005, 90: 1856-63.
24. Gola M, Bonadonna S, Mazziotti G, Amato G, Giustina A. Resistance to somatostatin analogs in acromegaly: an evolving concept? J Endocrinol Invest 2006, 29: 86-93.
25. van der Lely AJ, Muller AF, Janssen JA, et al. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist Pegvisomant in an acromegalic patient. J Clin Endocrinol Metab 2001, 86: 478-81.
26. Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002, 87: 3013-8.
27. Jorgensen JO, Feldt-Rasmussen U, Frystyk J, et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 2005, 90: 5627-31.
28. Aimaretti G, Boschetti M, Corneli G et al. Normal age-dependent values of serum insulin growth factor (IGF)-I: italian healthy population. J Endocrinol Invest 2007, in press.
29. Arosio M, Garrone S, Bruzzi P, Faglia G, Minuto F, Barreca A. Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3. J Clin Endocrinol Metab 2001, 86: 1091-8.
30. Drake WM, Loureiro RA, Parkinson C, Monson JP, Besser GM, Trainer PJ. Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant. Eur J Endocrinol 2005, 152: 47-51
31. Feenstra J, de Herder WW, ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005, 365: 1644-6.
32. Galland F, Kamenicky P, Affres H, et al. McCune-Albright syndrome and acromegaly: effects of hypothalamopituitary radiotherapy and/or pegvisomant in somatostatin analog-resistant patients. J Clin Endocrinol Metab 2006, 91: 4957-61.
33. Harris P, D'Souza G, Good A et al. A comparison between the efficacy and safety of pegvisomant to that of octreotide LAR in patients with acromegaly. Program of the 9th European Congress of Endocrinology, Budapest, Hungary, 2007, P610 (abstract).